newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announce